12/02/2022 – AB Science wishes to provide clarifications following press articles published after the public hearing of the Enforcement Committee of the French market regulator (AMF) on Friday, February 11, 2022 Download PDF Post navigationPreviousPrevious post:AB Science to present on its Amyotrophic Lateral Sclerosis (ALS) development program at the 2022 ALS Drug Development SummitNextNext post:Health Canada has granted authorization to file a New Drug Submission for masitinib in the treatment of ALS under the Notice of Compliance with Conditions (NOC/c) policyRelated PostsAB Science has received approval from the U.S. Food and Drug Administration (FDA) to initiate the confirmatory Phase 3 study with masitinib in the treatment of progressive multiple sclerosis29 December 2022Masitinib receives orphan drug status for the treatment of amyotrophic lateral sclerosis in Switzerland27 December 2022AB Science announces the drawdown of the first tranche of 6 million euros under its financing agreement with the European Investment Bank22 December 2022AB Science receives Notice of Deficiency (NOD) from Health Canada for masitinib in the treatment of amyotrophic lateral sclerosis (ALS)13 December 2022AB Science receives U.S. Food and Drug Administration (FDA) authorization to initiate confirmatory Phase 3 clinical study with masitinib in the treatment of Alzheimer’s Disease21 November 2022AB Science receives first agencies authorizations to initiate confirmatory Phase 3 clinical study with masitinib in the treatment of Alzheimer’s disease10 October 2022
AB Science has received approval from the U.S. Food and Drug Administration (FDA) to initiate the confirmatory Phase 3 study with masitinib in the treatment of progressive multiple sclerosis29 December 2022
Masitinib receives orphan drug status for the treatment of amyotrophic lateral sclerosis in Switzerland27 December 2022
AB Science announces the drawdown of the first tranche of 6 million euros under its financing agreement with the European Investment Bank22 December 2022
AB Science receives Notice of Deficiency (NOD) from Health Canada for masitinib in the treatment of amyotrophic lateral sclerosis (ALS)13 December 2022
AB Science receives U.S. Food and Drug Administration (FDA) authorization to initiate confirmatory Phase 3 clinical study with masitinib in the treatment of Alzheimer’s Disease21 November 2022
AB Science receives first agencies authorizations to initiate confirmatory Phase 3 clinical study with masitinib in the treatment of Alzheimer’s disease10 October 2022
